TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05324046

Intervention type: DIAGNOSTIC_TEST
Intervention: contrast-enhanced abdomen CT
Description: contrast-enhanced abdomen CT using dual-source CT scanner using A-tube (67% radiation) and B-tube (33% radiation).~* full dose CT data (A +B tubes, 100%) are reconstructed with iterative reconstruction (conventional)~* low dose CT data (A-tube only, B-tube only) are reconstructed with deep learning commercially available software.~* images are reconstructed using full dose (A- \& B- tubes) and smaller dose (A-tube only, B-tube only)
Study: NCT05980442

Intervention type: DEVICE
Intervention: Navigated total knee arthroplasty
Description: Total knee arthroplasty with Columbus® total knee endoprosthesis using the OrthoPilot® Elite navigation system

Intervention type: DEVICE
Intervention: Robot assisted total knee arthroplasty
Description: Total knee arthroplasty with Triathlon® total knee endoprosthesis using the MAKO® robot system
Study: NCT05345600

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MILTA probe
Description: Each woman will be included within the 6h after delivery (to ensure at least 2 days with the treatment / placebo). Once the written informed consent is obtained, the patient will be randomized in one of the 2 groups (MILTA or Placebo): 2 sessions are planned (the first one between 6h and 24h after delivery and the second one day after the first session). The woman will be lying on an exam bed. After a skin cleansing, the MILTA probe covered with a specific single use protection will be placed facing the scar. A 10-min session will include 5 min with the analgesia mode on followed with 5 min with the healing mode on in the MILTA group. For the placebo group, the procedure will be identical, with the probe switched OFF. To ensure that the red light is observable in the bedroom in both groups, a second probe will be used, facing the ceiling of the exam bedroom (and not the woman) for the 10 minutes of the procedure.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo probe
Description: Each woman will be included within the 6h after delivery (to ensure at least 2 days with the treatment / placebo). Once the written informed consent is obtained, the patient will be randomized in one of the 2 groups (MILTA or Placebo): 2 sessions are planned (the first one between 6h and 24h after delivery and the second one day after the first session). The woman will be lying on an exam bed. After a skin cleansing, the MILTA probe covered with a specific single use protection will be placed facing the scar. A 10-min session will include 5 min with the analgesia mode on followed with 5 min with the healing mode on in the MILTA group. For the placebo group, the procedure will be identical, with the probe switched OFF. To ensure that the red light is observable in the bedroom in both groups, a second probe will be used, facing the ceiling of the exam bedroom (and not the woman) for the 10 minutes of the procedure.
Study: NCT05485948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropeginterferon alfa-2b
Description: Initial dose of 250 µg at Week 0, a medium dose of 350 µg at Week 2, a target dose of 500 µg at Week 4, and a maintenance dose of 500 µg until Week 52.
Study: NCT06475144

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: online escape room teaching
Description: here are a total of eight game levels, each accompanied by video instructions or hints. Participants can proceed to the next room based on the level and hints, guiding their reasoning to the correct answers and achieving the learning objectives.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: online video-based teaching
Description: The study is divided into four units: SIRS Definition, Sepsis Definition and Classification, Sepsis Early Warning Scoring System, and Early Goal-Directed Therapy for Sepsis. Clinical case scenarios are animated for participants to watch, with content identical to the video prompts used in the experimental group's gameplay.
Study: NCT05568511

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: App-based exercise program
Description: Remotely-controlled, app-guided exercise program

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: These participants will follow the usual post-sepsis care after returning to home. The participants will be asked to log their daily activities in the app's health diary. The app will be activated for the baseline and follow-up physical function assessments, which will be supervised be a blinded coordinator via a video call.
Study: NCT05564169

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: treatment per os

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Masitinib (4.5)
Description: Masitinib (titration to 4.5 mg/kg/day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Cholinesterase inhibitors (donepezil, rivastigmine or galantamine) and/or memantine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care
Description: Cholinesterase inhibitors (donepezil, rivastigmine or galantamine) and/or memantine
Study: NCT05337332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide
Description: Suprachoroidal injection of triamcinolone acetonide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide
Description: Suprachoroidal injection of triamcinolone acetonide
Study: NCT05848154

Intervention type: DIAGNOSTIC_TEST
Intervention: ctDNA detection
Description: Blood samples are collected from patients at different time points during the monitoring process before treatment, after treatment, after surgery, and after adjuvant therapy/chemotherapy. ctDNA detection is performed on blood samples of all enrolled patients. WES and RNA-seq of samples from patients before and after treatment are performed to reveal the mechanisms of drug resistance.
Study: NCT06434480

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: * For intrahepatic progression: 27.5-50Gy in 5 fractions over 2 weeks will be given.~* For extrahepatic progression: an aim to give ablative dose will be given.
Study: NCT05009719

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prophylactic Donor lymphocytes infusions
Description: Donor lymphocytes is taken by apheresis or dose of blood from allogeneic donor. After apheresis lymphocytes arel freezed for next using. DLI is transfused to patients IV using central venous access.~Donor lymphocytes infusion start from D+60 - D+100 and continue with escalating doses every 1.5-3 months during first year after HSCT up to appearance of GVHD or signs of disease. First dose is 1\*10\*6 CD3+/kg. Subsequent doses increases by 0.5 log for haploidentical and unrelated donor and 1 log for sibling donor up to 1\*10\*8 CD3+/kg.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Preventive Donor lymphocytes infusions
Description: Donor lymphocytes is taken by apheresis or dose of blood from allogeneic donor. After apheresis lymphocytes freeze for next using. DLI are transfused to patients IV using central venous access.~Donor lymphocytes infusion continue with escalating doses every 1.5-3 months up to achieving MRD negative status or appearance of GVHD or signs of active disease.~First dose is 1\*10\*6 CD3+/kg for patients without previous GVHD and 1\*10\*5 CD3+/kg for patients with previous GVHD. Subsequent doses increases by 0.5 log for haploidentical and unrelated donor and 1 log for sibling donor up to 1\*10\*8 CD3+/kg.
Study: NCT04788628

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baseline
Description: Hippocampal and scalp EEG monitoring during overnight sleep

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor procedural memory task
Description: Training on the finger tapping MST prior to monitored overnight sleep with MST testing the following morning

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor procedural memory task plus auditory stimulation
Description: Training on the finger tapping MST prior to monitored overnight sleep that includes auditory stimulation, with MST testing the following morning
Study: NCT05098041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soticlestat
Description: Soticlestat tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Rifampin capsules.
Study: NCT03530410

Intervention type: DEVICE
Intervention: Intragastric balloon placement
Description: Patients will have endoscopic placement of intragastric balloon that will be removed endoscopically after 6 months
Study: NCT05102643

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 DNA Vaccine
Description: A novel vaccine developed for prophylaxis of COVID-19 based on HKU's PD-1-based DNA vaccine platform. It encodes a recombinant antigen comprising a soluble human PD-1 domain (i.e. programmed cell death protein, a member of the Cluster of Differentiation 28 (CD28) family) and the receptor binding domain (RBD) of SARS-CoV-2 (i.e. the key viral entry element).

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Solution for intramuscular injection
Study: NCT04904289

Intervention type: OTHER
Intervention: All intervention of real world
Description: We analyzed all data we can obtain from our databases

Intervention type: OTHER
Intervention: All intervention of real world
Description: We analyzed all data we can obtain from our databases
Study: NCT05335408

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acunex Vario intraocular lens
Description: This is an extended depth of focus IOL, made by Teleon Surgical B.V.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Alcon AcrySof IQ Vivity intraocular lens
Description: This is an extended depth of focus IOL, made by Alcon.
Study: NCT06170515

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: CareSens N-Eco (i-Sens), • CareSens N-Premier (i-Sens), CodeFree (SD Biosensor), GlucoNavii GDH (SD Biosensor)
Description: BGM Test

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Affinion (Abbott), HbA1c 501 (HemoCue), A1Care (iSens), DCA Vantage (Siemens)
Description: HbA1c Test
Study: NCT06212245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inebilizumab
Description: Participants will receive IV inebilizumab 300 mg
Study: NCT04754100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: agenT-797
Description: agenT-797 is an off-the-shelf cell therapy consisting of ≥ 95% allogeneic human unmodified iNKT cells isolated from 1 healthy donor mononuclear cell apheresis unit and expanded ex vivo.
Study: NCT06156085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan and Amoxicillin
Description: vonoprazan 20 mg and amoxicillin 1000 mg b.i.d. PC for 14days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole, Amoxicillin, Clarithromycin and Metronidazole
Description: lansoprazole 30 mg + amoxicillin 1000 mg b.i.d. AC for 7 days, followed by the same PPI + clarithromycin 500 mg + metronidazole 500 mg b.i.d. AC for 7 days
Study: NCT05882955

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recipes consumption
Description: Participants will eat one or two recipes a day for 17 weeks

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Recipes consumption
Description: Participants will eat one or two recipes a day for 17 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recipes consumption
Description: Participants will eat one or two recipes a day for 17 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hydroponic unit
Description: Participants will grow vitamin B12 biofortified plants for 17 weeks and consume (10 grams) of plant material for 11 weeks.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Hydroponic unit
Description: Participants will grow vitamin B12 biofortified plants for 17 weeks and consume (10 grams) of plant material for 11 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hydroponic unit
Description: Participants will grow vitamin B12 biofortified plants for 17 weeks and consume (10 grams) of plant material for 11 weeks.
Study: NCT04714541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Hcl 50Mg/Ml Inj
Description: Racemic Ketamine Will Be Infused At A Starting Dose of 0.75 mg/kg Over A Period of 45 Minutes. The Dose Will be Titrated, Based on Clinical Signs With Changes of 0.3mg/kg Up to Maximum of 0.95 mg/kg, and Lowest Dose of 0.3 mg/kg
Study: NCT05060588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril/Valsartan 49/51mg/Tab
Description: patients who meet the inclusion criteria are randomized to receive Sacubitril/Valsartan 24/26 mg once every 12 hours for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan 80mg/Tab
Description: Patients who meet the inclusion criteria are randomized to receive valsartan one tablet every 24 hours for 6 months.
Study: NCT06549569

Intervention type: PROCEDURE
Intervention: TFS
Description: burn coverage with TFS

Intervention type: PROCEDURE
Intervention: TFS
Description: burn coverage with TFS
Study: NCT06008990

Intervention type: DRUG
Intervention: Buprenorphine
Description: Pregnant mother must be taking Buprenorphine

Intervention type: DIAGNOSTIC_TEST
Intervention: Maternal Brain MRI
Description: Maternal Brain MRI obtained between 24-32 week gestation

Intervention type: DIAGNOSTIC_TEST
Intervention: Maternal Brain MRI
Description: Maternal Brain MRI obtained between 24-32 week gestation

Intervention type: OTHER
Intervention: Blood Samples
Description: During the MRI visit blood samples will be drawn: one hour prior to MRI, immediately before MRI, and one hour post MRI to test for Buprenorphine levels.

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Participants will answer questionnaires about their medical history, pregnancy, and substance use.

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Participants will answer questionnaires about their medical history, pregnancy, and substance use.
Study: NCT05483530

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HLX60 combined with HLX10
Description: five various doses of HLX60 combined with flat dose of HLX10
Study: NCT04937556

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic: Lactobacillus salivarius + Vit D + Zinc
Description: A mixture of 1\*10E9 colony forming unit (CFU) of Lactobacillus salivarius + Vit D + Zinc citrate in 1 capsule will be daily administrated during 28 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo in 1 capsule will be daily administrated during 28 days.
Study: NCT06057779

Intervention type: OTHER
Group type: OTHER
Intervention: Slow and heavy exercise therapy
Description: 6 sets of 10 single leg isolated eccentric heel drops into maximal dorsiflexion at an exercise speed of 0.33 Hz, with 1-min rest period between each set.

Intervention type: OTHER
Group type: OTHER
Intervention: Slow and light exercise therapy
Description: 6 sets of 10 single leg isolated eccentric heel drops into neutral ankle position at an exercise speed of 0.33 Hz, with 1-min rest period between each set.

Intervention type: OTHER
Group type: OTHER
Intervention: Fast and heavy exercise therapy
Description: 6 sets of 30 single leg isolated eccentric heel drops into maximal dorsiflexion at an exercise speed of 1 Hz, with 1-min rest period between each set.
Study: NCT05320900

Intervention type: DIAGNOSTIC_TEST
Intervention: Chest auscultation
Description: Chest auscultation data

Intervention type: DIAGNOSTIC_TEST
Intervention: Chest auscultation
Description: Chest auscultation data

Intervention type: DIAGNOSTIC_TEST
Intervention: Chest auscultation
Description: Chest auscultation data
Study: NCT05211479

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: educational intervention
Description: In the light of up-to-date information, Type I Diabetes Education Guide was created. With this guide, both face-to-face and tele-nursing training will be provided. Both working groups will receive training before starting research. The intervention group will continue their weekly training throughout the study.
Study: NCT05574205

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Exercise
Description: Supervised single-leg (unilateral) exercise will be undertaken every other day throughout the dietary intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Exercise
Description: Supervised single-leg (unilateral) exercise will be undertaken every other day throughout the dietary intervention

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein supplementation
Description: Participants will consume a protein supplement alongside a provided diet to control protein amount and quality.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein supplementation
Description: Participants will consume a protein supplement alongside a provided diet to control protein amount and quality.
Study: NCT05712187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALTO-100
Description: ALTO-100 tablet BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet BID
Study: NCT05501353

Intervention type: OTHER
Intervention: no intervention
Description: This study is an observational study, which does not affect the routine diagnosis and treatment of patients and only requires the collection of biological samples at specific nodes
Study: NCT04930055

Intervention type: BIOLOGICAL
Intervention: COVID-19 Vaccination
Description: Subjects will receive either the Moderna (mRNA-1273), Pfizer (BTN162b2), or Janssen (Ad26.COV2.S) vaccination per standard of care

Intervention type: BIOLOGICAL
Intervention: COVID-19 Vaccination
Description: Subjects will receive either the Moderna (mRNA-1273), Pfizer (BTN162b2), or Janssen (Ad26.COV2.S) vaccination per standard of care

Intervention type: BIOLOGICAL
Intervention: COVID-19 Vaccination
Description: Subjects will receive either the Moderna (mRNA-1273), Pfizer (BTN162b2), or Janssen (Ad26.COV2.S) vaccination per standard of care

Intervention type: BIOLOGICAL
Intervention: COVID-19 Vaccination
Description: Subjects will receive either the Moderna (mRNA-1273), Pfizer (BTN162b2), or Janssen (Ad26.COV2.S) vaccination per standard of care

Intervention type: BIOLOGICAL
Intervention: COVID-19 Vaccination
Description: Subjects will receive either the Moderna (mRNA-1273), Pfizer (BTN162b2), or Janssen (Ad26.COV2.S) vaccination per standard of care

Intervention type: BIOLOGICAL
Intervention: COVID-19 Vaccination
Description: Subjects will receive either the Moderna (mRNA-1273), Pfizer (BTN162b2), or Janssen (Ad26.COV2.S) vaccination per standard of care

Intervention type: BIOLOGICAL
Intervention: COVID-19 Vaccination
Description: Subjects will receive either the Moderna (mRNA-1273), Pfizer (BTN162b2), or Janssen (Ad26.COV2.S) vaccination per standard of care

Intervention type: BIOLOGICAL
Intervention: COVID-19 Vaccination
Description: Subjects will receive either the Moderna (mRNA-1273), Pfizer (BTN162b2), or Janssen (Ad26.COV2.S) vaccination per standard of care

Intervention type: BIOLOGICAL
Intervention: COVID-19 Vaccination
Description: Subjects will receive either the Moderna (mRNA-1273), Pfizer (BTN162b2), or Janssen (Ad26.COV2.S) vaccination per standard of care

Intervention type: BIOLOGICAL
Intervention: COVID-19 Vaccination
Description: Subjects will receive either the Moderna (mRNA-1273), Pfizer (BTN162b2), or Janssen (Ad26.COV2.S) vaccination per standard of care

Intervention type: BIOLOGICAL
Intervention: COVID-19 Vaccination
Description: Subjects will receive either the Moderna (mRNA-1273), Pfizer (BTN162b2), or Janssen (Ad26.COV2.S) vaccination per standard of care

Intervention type: BIOLOGICAL
Intervention: COVID-19 Vaccination
Description: Subjects will receive either the Moderna (mRNA-1273), Pfizer (BTN162b2), or Janssen (Ad26.COV2.S) vaccination per standard of care
Study: NCT04732182

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BrightGo cognitive training
Description: Training on the BrightGo experimental device in the home

Intervention type: DRUG
Group type: OTHER
Intervention: Standard of Care medication for early Alzheimer's Disease
Description: Participant takes 10 mg of Aricept daily or wears an Exelon 9.5 mg patch and is stable on one of these medications that were prescribed for diagnostic of early Alzheimer's Disease

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care medication for early Alzheimer's Disease
Description: Participant takes 10 mg of Aricept daily or wears an Exelon 9.5 mg patch and is stable on one of these medications that were prescribed for diagnostic of early Alzheimer's Disease
Study: NCT04717674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]Fluoropivalate ([18F]Fluoro-2,2-Dimethylpropionic Acid)
Description: \[18F\]FPIA radiotracer administration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET/CT
Description: PET/CT scan
Study: NCT05747911

Intervention type: OTHER
Description: Groups will not be intervened. Only observational data will be used.

Intervention type: OTHER
Description: Groups will not be intervened. Only observational data will be used.
Study: NCT04702165

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: lung resection with Lung Resection Marker Locator Kit
Description: Nodules eligible for surgical resection using the Lung Resection Marker Locator Kit
Study: NCT05586490

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Multifunctional RehabilitationDevice (MRD)
Description: Multifunctional rehabilitation device to treat mobility and cognitive problems in PwP

Intervention type: DEVICE
Group type: OTHER
Intervention: Multifunctional RehabilitationDevice (MRD)
Description: Multifunctional rehabilitation device to treat mobility and cognitive problems in PwP

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multifunctional RehabilitationDevice (MRD)
Description: Multifunctional rehabilitation device to treat mobility and cognitive problems in PwP

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: existing standard rehabilitation device
Description: existing standard rehabilitation device to be used for in-home comparison testing for aim 3
Study: NCT04839367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 64Cu-SAR-bisPSMA
Description: 64Cu-SAR-bisPSMA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 64Cu-SAR-bisPSMA
Description: 64Cu-SAR-bisPSMA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 64Cu-SAR-bisPSMA
Description: 64Cu-SAR-bisPSMA
Study: NCT04949698

Intervention type: DEVICE
Intervention: plasma exchange
Description: Plasma exchange was performed daily for five times or until platelet level returned to normal

Intervention type: DEVICE
Intervention: plasma exchange
Description: Plasma exchange was performed daily for five times or until platelet level returned to normal

Intervention type: DEVICE
Intervention: plasma exchange
Description: Plasma exchange was performed daily for five times or until platelet level returned to normal